MAUDE Adverse Event Report: LIVANOVA CANADA CORP. MITROFLOW LXA; TISSUE HEART VALVE

Model Number LXA19

Device Problems Calcified (1077); Material Too Rigid or Stiff (1544); Folded (2630); Material Deformation (2976); Material Twisted/Bent (2981); Insufficient Information (3190)

Patient Problems Aortic Valve Stenosis (1717); Death (1802)

Event Type  Death  

Event Description

A mitroflow lxa19 was implanted on (b)(6) 2011.A notification was received by a company representative stating that the patient died in mid - (b)(6) 2018.

Manufacturer Narrative

Gross examination performed on (b)(6) 2018 displayed the following results.The returned prosthesis was received with calcifications on leaflets.Visible pannus was present both on the inflow and outflow side.One leaflet appeared twisted.The manufacturing and material records for the mitroflow bioprosthetic pericardial heart valve, model # lxa19, s/n (b)(4), as they pertain to the reported event, were retrieved and reviewed by quality engineering at livanova (b)(4) corp.The results confirmed that this valve satisfied all material, visual, and performance standards required for a lxa19 mitroflow aortic pericardial heart valve at the time of manufacture and release.Leaflets calcification, detected with visual, x-ray and histological analyses, caused stiffening and led to progressive valve stenosis.Pannus tissue overgrowth into the inflow lumen also contributed to valve stenosis.Aortic insufficiency likely resulted from leaflets tears.There was no evidence of endocarditis in the returned valve.As reported in the scientific literature (1,2,3,4,5), structural dysfunction is the major cause of failure of bioprosthetic heart valves and the principal underlying pathologic process is cuspal calcification.Calcification can also cause stenosis due to cuspal stiffening.Calcific deposits are usually localized to cuspal tissue (intrinsic calcification).Histological analysis, performed in this mitroflow valve, showed the presence of lipid infiltration (cholesterol clefts) in the leaflet pericardial tissue.This lipid infiltration, as supported from the scientific literature (2,3,4,5) may contribute to localized leaflet stiffness, and if associated with a degeneration of collagen fibers, as detected in the samples from this mitroflow valve, may lead to leaflet tears.The presence of focal gram + is not attributable to an infective endocarditis in the acute phase.Calcification in a biological valve is a known inherent risk identified in the manufacturing ifu.The analysis provides evidence that the root cause of the adverse event leading to explant was a result of structural valve deterioration.However, because the exact date of patient death is unknown, it is inconclusive if the valve explant resulted in patient death.Frederick j.Schoen, md, phd, and robert j.Levy, md; calcification of tissue heart valve substitutes: progress toward understanding and prevention.Ann thorac surg 1073 2005; 79:1072-80.Shetty r, girerd n, cote n, arsenault b, despres jp, pibarot p, mathieu p; elevated proportion of small, dense low-density lipoprotein particles and lower adiponectin blood levels predict early structural valve degeneration of bioprostheses.Cardiology ,2012 ;121(1):20-6.Shetty r, pibarot p, audet a, et al.; lipid-mediated inflammation and degeneration of bioprosthetic heart valves.Eur j clin invest.2009 jun;39(6):471-80.Nollert g, miksch j, kreuzer e, reichart b.; risk factors for atherosclerosis and the degeneration of pericardia! valves after aortic valve replacement.J thorac cardiovasc surg 2003;126:965-8.Martin briand, ms; philippe pibarot, dvm, phd; jean-pierre despre·s, phd; pierre voisine, md;jean g.Dumesnil, md; francois dagenais, md; patrick mathieu, md; metabolic syndrome is associated with faster degeneration of bioprosthetic valves.Circulation.2006;114:1-512-1-517.

• Brand Name: MITROFLOW LXA
• Type of Device: TISSUE HEART VALVE
• Manufacturer (Section D): LIVANOVA CANADA CORP.; 5005 north fraser way; burnaby, bc V5J 5 M1; CA V5J 5M1
• Manufacturer (Section G): LIVANOVA CANADA CORP; 5005 north fraser way; burnaby, bc
• Manufacturer Contact: francesca crovato ; 5005 north fraser way; burnaby, bc
• MDR Report Key: 7359210
• MDR Text Key: 103100401
• Report Number: 3004478276-2018-00154
• Device Sequence Number: 1
• Product Code: LWR
• UDI-Device Identifier: 00896208000092
• UDI-Public: (01)00896208000092(240)LXA19(17)160331
• Combination Product (y/n): N
• Reporter Country Code: UK
• PMA/PMN Number: P060038
• Number of Events Reported: 1
• Summary Report (Y/N): N
• Report Source: Manufacturer
• Source Type: company representative,health
• Reporter Occupation: Physician
• Type of Report: Initial,Followup
• Report Date: 04/25/2018

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Date FDA Received: 03/21/2018
• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Device Operator: Physician
• Device Expiration Date: 03/31/2016
• Device Model Number: LXA19
• Device Catalogue Number: LXA19
• Was Device Available for Evaluation?: Yes
• Is the Reporter a Health Professional?: Yes
• Date Manufacturer Received: 03/28/2018
• Was Device Evaluated by Manufacturer?: No
• Date Device Manufactured: 04/08/2011
• Is the Device Single Use?: Yes
• Is This a Reprocessed and Reused Single-Use Device?: No
• Type of Device Usage: Initial
• Patient Sequence Number: 1
• Patient Outcome(s): Death
• Patient Weight: 79